Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligufalimab (AK117) in advanced solid tumors or lymphomas
NCT04728334Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ligufalimab in solid tumor (advanced stage) and non-Hodgkin lymphoma (NHL), sponsored by Akeso, Inc. Primary endpoints: Number of participants with adverse events and Number of participants with a Dose Limiting Toxicity. Started Mar 2021; status: completed.
02
Drugs
ligufalimab
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04728334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728334.